Cash and Cash Equivalents, at Carrying Value of Nurix Therapeutics, Inc. from 30 Nov 2018 to 30 Nov 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Summary
Nurix Therapeutics, Inc. quarterly Cash and Cash Equivalents, at Carrying Value in USD history and change rate from 30 Nov 2018 to 30 Nov 2025.
  • Nurix Therapeutics, Inc. Cash and Cash Equivalents, at Carrying Value for the quarter ending 30 Nov 2025 was $246,960,000, a 125% increase year-over-year.
Source SEC data
View on sec.gov
Cash and Cash Equivalents, at Carrying Value, Quarterly (USD)
Cash and Cash Equivalents, at Carrying Value, YoY Quarterly Change (%)

Nurix Therapeutics, Inc. Quarterly Cash and Cash Equivalents, at Carrying Value (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $246,960,000 +$136,963,000 +125% 30 Nov 2025 10-K 28 Jan 2026 2025 FY
Q3 2025 $78,438,000 -$20,606,000 -21% 31 Aug 2025 10-Q 09 Oct 2025 2025 Q3
Q2 2025 $84,260,000 -$32,530,000 -28% 31 May 2025 10-Q 09 Jul 2025 2025 Q2
Q1 2025 $75,916,000 +$26,103,000 +52% 28 Feb 2025 10-Q 08 Apr 2025 2025 Q1
Q4 2024 $109,997,000 +$55,370,000 +101% 30 Nov 2024 10-K 28 Jan 2026 2025 FY
Q3 2024 $99,044,000 +$56,740,000 +134% 31 Aug 2024 10-Q 09 Oct 2025 2025 Q3
Q2 2024 $116,790,000 +$57,832,000 +98% 31 May 2024 10-Q 09 Jul 2025 2025 Q2
Q1 2024 $49,813,000 +$16,242,000 +48% 29 Feb 2024 10-Q 08 Apr 2025 2025 Q1
Q4 2023 $54,627,000 -$9,847,000 -15% 30 Nov 2023 10-K 28 Jan 2026 2025 FY
Q3 2023 $42,304,000 -$5,252,000 -11% 31 Aug 2023 10-Q 11 Oct 2024 2024 Q3
Q2 2023 $58,958,000 +$17,425,000 +42% 31 May 2023 10-Q 11 Jul 2024 2024 Q2
Q1 2023 $33,571,000 -$45,209,000 -57% 28 Feb 2023 10-Q 10 Apr 2024 2024 Q1
Q4 2022 $64,474,000 -$16,032,000 -20% 30 Nov 2022 10-K 28 Jan 2025 2024 FY
Q3 2022 $47,556,000 -$99,884,000 -68% 31 Aug 2022 10-Q 12 Oct 2023 2023 Q3
Q2 2022 $41,533,000 -$146,674,000 -78% 31 May 2022 10-Q 13 Jul 2023 2023 Q2
Q1 2022 $78,780,000 -$47,601,000 -38% 28 Feb 2022 10-Q 13 Apr 2023 2023 Q1
Q4 2021 $80,506,000 -$38,850,000 -33% 30 Nov 2021 10-K 09 Feb 2023 2022 FY
Q3 2021 $147,440,000 -$118,087,000 -44% 31 Aug 2021 10-Q 14 Oct 2021 2021 Q3
Q2 2021 $188,207,000 31 May 2021 10-Q 13 Jul 2021 2021 Q2
Q1 2021 $126,381,000 28 Feb 2021 10-Q 13 Apr 2021 2021 Q1
Q4 2020 $119,356,000 +$84,540,000 +243% 30 Nov 2020 10-K 28 Jan 2022 2021 FY
Q3 2020 $265,527,000 +$213,678,000 +412% 31 Aug 2020 10-Q 14 Oct 2020 2020 Q3
Q4 2019 $34,816,000 +$9,225,000 +36% 30 Nov 2019 10-K 16 Feb 2021 2020 FY
Q3 2019 $51,849,000 31 Aug 2019 10-Q 14 Oct 2020 2020 Q3
Q4 2018 $25,591,000 30 Nov 2018 10-Q 14 Oct 2020 2020 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.